3月4日,格兰德制药有限公司宣布,其酒石酸溴莫尼定滴眼液已获得美国食品药品监督管理局的暂时批准。这一进展标志着该公司在眼科用药领域取得重要突破。
酒石酸溴莫尼定滴眼液主要用于治疗开角型青光眼或高眼压症。此次获得暂时批准意味着该药品已满足FDA关于安全性、有效性和质量的审评标准,为后续正式上市销售奠定基础。
3月4日,格兰德制药有限公司宣布,其酒石酸溴莫尼定滴眼液已获得美国食品药品监督管理局的暂时批准。这一进展标志着该公司在眼科用药领域取得重要突破。
酒石酸溴莫尼定滴眼液主要用于治疗开角型青光眼或高眼压症。此次获得暂时批准意味着该药品已满足FDA关于安全性、有效性和质量的审评标准,为后续正式上市销售奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.